10329-41-6Relevant articles and documents
Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. 2. Synthesis and structure-activity relationships of α,α-cycloalkylglycine sulfonamides
Fattori, Daniela,Rossi, Cristina,Fincham, Christopher I.,Caciagli, Valerio,Catrambone, Fernando,D'Andrea, Piero,Felicetti, Patrizia,Gensini, Martina,Marastoni, Elena,Nannicini, Rossano,Paris, Marielle,Terracciano, Rosa,Bressan, Alessandro,Giuliani, Sandro,Maggi, Carlo A.,Meini, Stefania,Valenti, Claudio,Quartara, Laura
, p. 550 - 565 (2007/10/03)
Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.
